Sara YaoSara Sinicropi-Yao

Sara Sinicropi-Yao, Ph.D.

Principal Scientist, Translational Biology

Before joining Auron Therapeutics, Sara was an Investigator in the Tumor Biology group at H3 Biomedicine, where she led three RAS/RAF/MAPK drug discovery programs and was a member of the Target Discovery Initiative team. At Sanofi in Cambridge, MA, she led a cross-functional postdoctoral project across the pharmacology, genomics, and bioinformatics teams to understand how to convert immune cold tumors to be responsive to therapy. These efforts advanced a combination treatment into the clinic. During Sara’s industrial career she has focused on driving drug discovery projects from target identification to the clinic.

Her post-doctoral research program at The Ohio State University Comprehensive Cancer Center, Columbus, OH sought to identify molecular features associated with brain-tropic metastasis in lung cancer. Sara earned her Ph.D in Biomedical Sciences with an emphasis in Computational Biology and Bioinformatics at The Ohio State University Medical School where she pioneered an interdisciplinary approach to understand the role of Notch in lung cancer. Prior to graduate school, Sara worked at three companies including Eli-Lilly and Biogen-Idec as an Associate Scientist to develop Fc Effector Function assays. During college she completed two summer internships at Abbott. Sara earned her B.S. in Sociology and Minor in Chemistry from Bates College, Lewiston, ME.

Sara resides in Boston, MA with her dog. Her hobbies include reading, running, hiking, painting, and gardening.